DE602008021800C5 - Antibiotikum zur Behandlung von lokaler Infektion - Google Patents
Antibiotikum zur Behandlung von lokaler Infektion Download PDFInfo
- Publication number
- DE602008021800C5 DE602008021800C5 DE602008021800.7A DE602008021800A DE602008021800C5 DE 602008021800 C5 DE602008021800 C5 DE 602008021800C5 DE 602008021800 A DE602008021800 A DE 602008021800A DE 602008021800 C5 DE602008021800 C5 DE 602008021800C5
- Authority
- DE
- Germany
- Prior art keywords
- patient
- antibiotic
- disease
- sample
- local infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Antibiotic for the use in the treatment of a local infection for the prevention of a further disease or medical condition which has not yet been manifested in a patient having a primary disease, wherein said primary disease is not an infection and is not heart failure, wherein said further disease or medical condition is not sepsis, and wherein the antibiotic is administered when the level of procalcitonin or fragments thereof of at least 12 amino acids in length, in a sample of the patient selected from the group comprising a blood sample, a serum sample and a plasma sample, is between 0.02 and 0.1 ng/mL.
Description
- Der X. Zivilsenat des Bundesgerichtshofs hat auf die mündliche Verhandlung vom 14. Dezember 2021 für Recht erkannt:
- Auf die Berufung wird das Urteil des 3. Senats (Nichtigkeitssenats) des Bundespatentgerichts vom 23. Juli 2019 unter Zurückweisung des weitergehenden Rechtsmittels abgeändert.
Claims (2)
- Antibiotic for the use in the treatment of a local infection for the prevention of a further disease or medical condition which has not yet been manifested in a patient having a primary disease, wherein said primary disease is not an infection and is not heart failure, wherein said further disease or medical condition is not sepsis, and wherein the antibiotic is administered when the level of procalcitonin or fragments thereof of at least 12 amino acids in length, in a sample of the patient selected from the group comprising a blood sample, a serum sample and a plasma sample, is between 0.02 and 0.1 ng/mL.
- Ein Antibiotikum gemäß
Anspruch 1 , wobei das Risiko, sich eine weitere Erkrankung oder weitere medizinische Beschwerden zuzuziehen abnimmt, wenn der besagte Patient mit einem Antibiotikum behandelt wird.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07015271A EP2020603A1 (de) | 2007-08-03 | 2007-08-03 | Verfahren zur Einteilung von Risikoklassen bei stabiler Erkrankung der Koronaraterien |
EP07015271 | 2007-08-03 | ||
EP08152651 | 2008-03-12 | ||
EP08152651A EP2101178A1 (de) | 2008-03-12 | 2008-03-12 | Verwendung von Procalcitonin zur Prognose folgender akuter Koronarsyndromen |
EP10188287A EP2301626B1 (de) | 2007-08-03 | 2008-08-01 | Antibiotikum zur Behandlung von lokaler Infektion |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602008021800C5 true DE602008021800C5 (de) | 2022-05-05 |
Family
ID=39745280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602008021800.7A Active DE602008021800C5 (de) | 2007-08-03 | 2008-08-01 | Antibiotikum zur Behandlung von lokaler Infektion |
Country Status (9)
Country | Link |
---|---|
US (3) | US20110136161A1 (de) |
EP (4) | EP2301626B1 (de) |
JP (2) | JP5059943B2 (de) |
CN (3) | CN110346577A (de) |
AT (2) | ATE533061T1 (de) |
DE (1) | DE602008021800C5 (de) |
ES (3) | ES2377112T3 (de) |
HK (1) | HK1183707A1 (de) |
WO (1) | WO2009019230A2 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2377112T3 (es) | 2007-08-03 | 2012-03-22 | B.R.A.H.M.S Gmbh | Método para el diagnóstico de una infección bacteriana |
HUE046182T2 (hu) * | 2009-04-14 | 2020-02-28 | Brahms Gmbh | Az antibiotikumos kezelés kozkázatának becslése elsõdlegesen nem fertõzõ betegségben szenvedõ betegekben a prokalcitonin szintjének meghatározásával |
CN102449486B (zh) * | 2009-06-05 | 2015-01-21 | B.R.A.H.M.S有限公司 | 在患有呼吸困难的对象中检测细菌感染 |
DK2470910T3 (en) | 2009-08-28 | 2017-04-03 | Brahms Gmbh | Procalcitonin for the prognosis of side effects |
EP2320237B1 (de) | 2009-10-13 | 2016-08-03 | B.R.A.H.M.S GmbH | Procalcitonin zur Diagnose von bakteriellen Infektionen und Führung der Antibiotikabehandlung bei Menschen mit akutem Schlaganfall oder transienten ischämischen Anfällen |
JP5798133B2 (ja) * | 2010-03-08 | 2015-10-21 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不特定の愁訴を示す患者における細菌感染及び抗生物質治療の指標を診断するために用いられるプロカルシトニン |
ITRM20100121A1 (it) * | 2010-03-18 | 2011-09-19 | Univ Pisa | Marcatori molecolari per infezioni delle vie urinarie. |
US20140051183A1 (en) * | 2010-06-18 | 2014-02-20 | B.R.A.H.M.S Gmbh | Biomarkers for the prediction of incident cancer |
US20130024205A1 (en) * | 2011-07-18 | 2013-01-24 | International Business Machines Corporation | Dynamically updating electronic medical records and leveraging a person's path in a facility to mitgate risks |
EP3367099B1 (de) | 2012-02-09 | 2021-05-26 | Memed Diagnostics Ltd. | Signaturen und determinanten zur diagnose von infektionen und verfahren zur verwendung davon |
WO2013153177A1 (en) * | 2012-04-12 | 2013-10-17 | B.R.A.H.M.S Gmbh | Prognosis of adverse events in patients with suspected chronic heart failure |
EP2849729B1 (de) | 2012-05-18 | 2018-11-14 | Critical Care Diagnostics, Inc. | Verfahren zur behandlung oder vorhersage des risikos des ereignisses von ventrikulärer tachyarrhythmie |
ES2656897T3 (es) * | 2012-08-16 | 2018-02-28 | Critical Care Diagnostics, Inc. | Procedimientos de predicción del riesgo de desarrollar hipertensión |
EP2920591A4 (de) | 2012-11-15 | 2016-10-19 | Ortho Clinical Diagnostics Inc | Kalibrierungsassays mit reaktionszeitnutzung |
CN107076746B (zh) | 2014-08-14 | 2020-05-29 | 米密德诊断学有限公司 | 使用流形和超平面进行生物学数据的计算机分析 |
US20170234873A1 (en) | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
US20180224464A1 (en) * | 2015-06-09 | 2018-08-09 | Osaka University | Method of predicting and determining therapeutic effect on rheumatoid arthritis due to biological formulation |
CA3015046A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
CN106093416B (zh) * | 2016-05-18 | 2018-10-12 | 北京北方生物技术研究所有限公司 | 一种一步法检测降钙素原的试剂盒及其制备方法 |
US11340223B2 (en) | 2016-07-10 | 2022-05-24 | Memed Diagnostics Ltd. | Early diagnosis of infections |
CA3027341A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
EP3519833A4 (de) | 2016-09-29 | 2020-06-03 | MeMed Diagnostics Ltd. | Verfahren zur prognose und behandlung |
US11353456B2 (en) | 2016-09-29 | 2022-06-07 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification for appendicitis |
EP3682241B1 (de) * | 2017-09-13 | 2022-03-30 | B.R.A.H.M.S GmbH | Pct und adm als marker zur überwachung von antibiotikabehandlung |
JP7444776B2 (ja) * | 2017-12-20 | 2024-03-06 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併存症を有する患者におけるプロカルシトニンに基づく抗生物質療法のガイダンス |
US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
EP4256331A1 (de) * | 2020-12-02 | 2023-10-11 | Beckman Coulter, Inc. | Nachweis von medizinischen zuständen, schweregrad, risiko und sehschärfe unter verwendung von parametern |
US20240219405A1 (en) | 2021-04-30 | 2024-07-04 | Roche Diagnostics Operations, Inc. | Il6 marker panels for early detection of sepsis |
CN117295950A (zh) | 2021-04-30 | 2023-12-26 | 豪夫迈·罗氏有限公司 | 用于脓毒症的早期检测的ngal标志物组 |
CN117597584A (zh) | 2021-04-30 | 2024-02-23 | 豪夫迈·罗氏有限公司 | 用于脓毒症的早期检测的esm1标志物组合 |
EP4330687A2 (de) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Sflt1-markertafeln zur frühen erkennung von sepsis |
US20240219404A1 (en) | 2021-04-30 | 2024-07-04 | Roche Diagnostics Operations, Inc. | Igfbp7 marker panels for early detection of sepsis |
JP2024514676A (ja) | 2021-04-30 | 2024-04-02 | エフ. ホフマン-ラ ロシュ アーゲー | 敗血症の早期検出用のpctマーカーパネル |
EP4330682A2 (de) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Präsepsinmarkertafeln zur frühen erkennung von sepsis |
CN117280218A (zh) | 2021-04-30 | 2023-12-22 | 豪夫迈·罗氏有限公司 | 用于脓毒症的早期检测的strem1标志物组 |
CN117203528A (zh) | 2021-04-30 | 2023-12-08 | 豪夫迈·罗氏有限公司 | 用于脓毒症的早期检测的gdf15标志物组 |
WO2023052446A1 (en) | 2021-09-29 | 2023-04-06 | F. Hoffmann-La Roche Ag | Mr-proadm marker panels for early detection of sepsis |
WO2023156655A1 (en) | 2022-02-21 | 2023-08-24 | F. Hoffmann-La Roche Ag | Dll1 marker panels for early detection of sepsis |
EP4357778A1 (de) | 2022-10-20 | 2024-04-24 | Heraeus Medical GmbH | Behandlung von mikrobiellen infektionen mit diagnose durch biomarker d-lactat |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4227454C1 (de) | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
US6147688A (en) | 1993-06-28 | 2000-11-14 | Athena Design Systems, Inc. | Method and apparatus for defining and selectively repeating unit image cells |
US5795725A (en) | 1995-04-18 | 1998-08-18 | Biosite Diagnostics Incorporated | Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays |
DE19600875C1 (de) * | 1996-01-12 | 1997-06-26 | Brahms Diagnostica Gmbh | Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse |
US6156521A (en) | 1997-12-19 | 2000-12-05 | Biosite Diagnostics, Inc. | Methods for the recovery and measurement of troponin complexes |
US5993811A (en) * | 1997-02-03 | 1999-11-30 | Biology Associates, Llc | Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis |
US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
DE19903336C2 (de) | 1999-01-28 | 2000-12-14 | Brahms Diagnostica Gmbh | Gebrauchsfertige Kalibratoren für die Bestimmung von Procalcitonin |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040253637A1 (en) * | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
JP3806694B2 (ja) * | 2001-05-04 | 2006-08-09 | バイオサイト インコーポレイテッド | 急性冠状動脈症候群の診断マーカーおよびその使用方法 |
JP2006526140A (ja) | 2002-12-24 | 2006-11-16 | バイオサイト インコーポレイテッド | 鑑別診断のためのマーカーおよびその使用方法 |
DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
JP2006527190A (ja) | 2003-04-17 | 2006-11-30 | サイファージェン バイオシステムズ インコーポレイテッド | ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法 |
US20050148029A1 (en) | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
US20050170443A1 (en) * | 2003-10-03 | 2005-08-04 | Scantibodies Laboratory, Inc. | Methods and use of binding components for improving assay specificity |
CA2485722A1 (en) | 2003-10-22 | 2005-04-22 | Paul Lehmann | Soluble transferrin receptor |
EP1564558B1 (de) | 2004-02-13 | 2005-12-07 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur Bestimmung der Bildung von Endothelinen zu Zwecken der medizinischen Diagnostik, sowie Antikörper und Kits für die Durchführung eines solchen Verfahrens |
US20060024744A1 (en) | 2004-07-28 | 2006-02-02 | Mills Rhonda A | Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte |
DE102004041659A1 (de) | 2004-08-27 | 2006-03-02 | Institut Virion/Serion Gmbh | Testvorrichtung für die in vitro Diagnostik von Multianalyt-Tests und deren Verwendung |
CA2612450C (en) | 2005-06-28 | 2014-04-29 | Zbx Corporation | Membrane array and analytical device |
DE102005034174A1 (de) * | 2005-07-21 | 2007-02-08 | B.R.A.H.M.S Ag | Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen |
AU2006299417A1 (en) * | 2005-10-03 | 2007-04-12 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes |
CN1800384A (zh) * | 2005-11-08 | 2006-07-12 | 浙江大学 | 降钙素原的制备方法 |
EP2005168A4 (de) | 2006-03-09 | 2009-05-20 | Biosite Inc | Verfahren und zusammensetzung zur diagnose von krankheiten der aorta |
DE102006046996A1 (de) | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
EP2020603A1 (de) | 2007-08-03 | 2009-02-04 | BRAHMS Aktiengesellschaft | Verfahren zur Einteilung von Risikoklassen bei stabiler Erkrankung der Koronaraterien |
ES2377112T3 (es) | 2007-08-03 | 2012-03-22 | B.R.A.H.M.S Gmbh | Método para el diagnóstico de una infección bacteriana |
DE102008037108A1 (de) | 2008-08-08 | 2010-02-11 | Samson Aktiengesellschaft | System zum Stellen eines Stellorgans |
EP2320237B1 (de) * | 2009-10-13 | 2016-08-03 | B.R.A.H.M.S GmbH | Procalcitonin zur Diagnose von bakteriellen Infektionen und Führung der Antibiotikabehandlung bei Menschen mit akutem Schlaganfall oder transienten ischämischen Anfällen |
US20110263438A1 (en) | 2010-04-22 | 2011-10-27 | Mehmet Ali Soylemez | Diagnosis and complication risk assessment of pancreatic diabetes using procalcitonin |
-
2008
- 2008-08-01 ES ES10188288T patent/ES2377112T3/es active Active
- 2008-08-01 EP EP10188287A patent/EP2301626B1/de active Active
- 2008-08-01 ES ES10188287T patent/ES2403310T3/es active Active
- 2008-08-01 EP EP10188289A patent/EP2293076B1/de active Active
- 2008-08-01 US US12/671,702 patent/US20110136161A1/en not_active Abandoned
- 2008-08-01 WO PCT/EP2008/060176 patent/WO2009019230A2/en active Application Filing
- 2008-08-01 EP EP08786791A patent/EP2174143B1/de active Active
- 2008-08-01 CN CN201910283751.1A patent/CN110346577A/zh active Pending
- 2008-08-01 DE DE602008021800.7A patent/DE602008021800C5/de active Active
- 2008-08-01 AT AT10188288T patent/ATE533061T1/de active
- 2008-08-01 CN CN201210451017.XA patent/CN103123359B/zh active Active
- 2008-08-01 EP EP10188288A patent/EP2293078B1/de active Active
- 2008-08-01 AT AT08786791T patent/ATE514091T1/de active
- 2008-08-01 CN CN200880101846A patent/CN101790687A/zh active Pending
- 2008-08-01 JP JP2010518695A patent/JP5059943B2/ja active Active
- 2008-08-01 ES ES10188289T patent/ES2401703T3/es active Active
-
2011
- 2011-02-25 US US13/034,752 patent/US10456364B2/en active Active
-
2012
- 2012-08-02 JP JP2012171897A patent/JP5185460B2/ja active Active
-
2013
- 2013-09-27 HK HK13111067.0A patent/HK1183707A1/xx unknown
-
2019
- 2019-03-29 US US16/369,966 patent/US11241395B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2174143B1 (de) | 2011-06-22 |
CN103123359B (zh) | 2015-07-29 |
US10456364B2 (en) | 2019-10-29 |
JP5185460B2 (ja) | 2013-04-17 |
EP2293076B1 (de) | 2012-12-19 |
JP5059943B2 (ja) | 2012-10-31 |
EP2293076A3 (de) | 2011-03-30 |
EP2301626A2 (de) | 2011-03-30 |
HK1183707A1 (en) | 2014-01-03 |
ES2401703T3 (es) | 2013-04-23 |
CN103123359A (zh) | 2013-05-29 |
EP2293076A2 (de) | 2011-03-09 |
US20110152170A1 (en) | 2011-06-23 |
JP2012237760A (ja) | 2012-12-06 |
CN101790687A (zh) | 2010-07-28 |
EP2293078B1 (de) | 2011-11-09 |
WO2009019230A3 (en) | 2009-04-23 |
EP2174143A2 (de) | 2010-04-14 |
ATE533061T1 (de) | 2011-11-15 |
US11241395B2 (en) | 2022-02-08 |
US20110136161A1 (en) | 2011-06-09 |
CN110346577A (zh) | 2019-10-18 |
ES2403310T3 (es) | 2013-05-17 |
JP2010536012A (ja) | 2010-11-25 |
ES2377112T3 (es) | 2012-03-22 |
EP2301626A3 (de) | 2011-11-16 |
ATE514091T1 (de) | 2011-07-15 |
EP2293078A3 (de) | 2011-04-06 |
EP2301626B1 (de) | 2013-01-16 |
WO2009019230A4 (en) | 2009-06-25 |
WO2009019230A2 (en) | 2009-02-12 |
EP2293078A2 (de) | 2011-03-09 |
US20190224135A1 (en) | 2019-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602008021800C5 (de) | Antibiotikum zur Behandlung von lokaler Infektion | |
US6130206A (en) | Treating viral infections associated with chronic fatigue with dsRNA | |
Roy | Hysterical seizures | |
ATE554395T1 (de) | Diagnose septischer komplikationen | |
Munoz-Hernandez et al. | Obstructive sleep apnoea syndrome, endothelial function and markers of endothelialization. Changes after CPAP | |
MX2021013424A (es) | Combinacion de marcador de mirna y kit para el diagnostico del cancer gastrico. | |
EP2287340A3 (de) | Verfahren zur Diagnose und Behandlung einer Geisteskrankheit | |
BR0309638A (pt) | Polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, ligando, composto, método de diagnóstico de uma doença em um paciente, uso de um polipeptìdeo, composição farmacêutica, composição de vacina, métodos de tratamento de uma doença em um paciente, de monitoração do tratamento terapêutico de doença em um paciente, e de identificação de um composto que é eficaz no tratamento e/ou no diagnóstico de doença, kit, animal não humano knockout ou transgênico, e, método para a seleção de um composto eficaz para o tratamento de doença | |
WO2007015113A3 (en) | New protein isoforms of the pif-family and uses thereof | |
BR0208870A (pt) | Proteìna associada à doença | |
RU2012121096A (ru) | Биомаркер меланомы | |
Tumturk et al. | Emergency resection of brainstem cavernous malformations | |
AU684288B2 (en) | Diagnosing and treating chronic fatigue syndrome | |
Schady et al. | Sensory neuropathy in hereditary spastic paraplegia. | |
Travlos et al. | Cerebrospinal fluid cell count following spinal cord injury | |
Hamad et al. | Measuring inflammation in patients with allergic rhinitis using different biomarkers | |
Yancey et al. | Cysticercosis: recent advances in diagnosis and management of neurocysticercosis | |
Gupta et al. | A prospective comparative study of bedside index for assessing severity in acute pancreatitis, APACHE II and computed tomography severity index scoring in predicting outcome in acute pancreatitis | |
Switała et al. | Genetic aspects of pain and its variability in the human population | |
Artem et al. | Analysis of the severity of oxidative stress and the level of apoptosis marker, annexin a5, in relation to the dental indices in bronchiectasis-associated chronic generalized periodontitis | |
Tian et al. | A novel homozygous desmin nonsense mutation causes pediatric onset autosomal recessive desminopathy with severe cardiomyopathy | |
WO2023196576A3 (en) | Methods and compositions for detecting or treating neurological diseases and hematological malignancies. | |
Mahmoud et al. | Critical illness myopathy and polyneuropathy in children admitted to the ICU | |
Chain et al. | frontiers Frontiers in Neurology CASE REPORT published: 11 July 2022 | |
LU93323B1 (en) | Method for diagnosing different forms of malaria |